A Study to Evaluate Pazopanib Tablets in Patients Who Have Neovascular Age-related Macular Degeneration
Status:
Completed
Trial end date:
2011-04-29
Target enrollment:
Participant gender:
Summary
A study to evaluate pazopanib tablets in male and female adults of non-child bearing
potential with subfoveal CNV due to neovascular AMD. The goal is to assess safety and how
well the subjects tolerate the drug. The study will also look at how the body breaks down and
metabolizes the drug. All subjects will start the study up to 8 days prior to receiving drug.
Once started subjects will take one tablet each day for 28 days. A follow up visit will occur
approximately 2 weeks after drug is stopped.